Ligand completes $75M purchase of Agenus royalty rights

LIGAND PHARMACEUTICALS INC

Completed purchase of royalty rights from Agenus Inc. for $75M on May 29, 2024.
Transaction previously announced on May 7, 2024; customary closing conditions satisfied.
No other terms or financial impact disclosed beyond the purchase price.

item 8.01

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.